DENALI THERAPEUTICS IN

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi

25 1 2023 08:00:00 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases

09 1 2023 08:00:44 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial

05 12 2022 07:00:41 提供 Nasdaq GlobeNewswire

Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

03 11 2022 16:01:44 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN

01 11 2022 08:00:02 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

24 10 2022 16:30:04 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock

19 10 2022 21:19:42 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Proposed Offering of Common Stock

18 10 2022 16:40:50 提供 Nasdaq GlobeNewswire

Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations

03 10 2022 08:00:39 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022

31 8 2022 08:00:01 提供 Nasdaq GlobeNewswire

Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

08 8 2022 16:01:01 提供 Nasdaq GlobeNewswire

Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease

31 5 2022 08:00:02 提供 Nasdaq GlobeNewswire

Denali Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

05 5 2022 16:01:01 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi

02 5 2022 08:30:00 提供 Nasdaq GlobeNewswire

Denali Therapeutics Appoints Alexander Schuth as Chief Operating and Financial Officer as Steve Krognes Transitions to Denali Board of Directors

15 3 2022 16:30:28 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of DNL593 (PTV:PGRN) for Frontotemporal Dementia-Granulin (FTD-GRN)

09 3 2022 08:00:01 提供 Nasdaq GlobeNewswire

Denali Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

28 2 2022 16:01:00 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial

10 2 2022 08:00:01 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Appointment of Erik Harris to Board of Directors

07 2 2022 09:00:01 提供 Nasdaq GlobeNewswire

Denali Therapeutics Announces Presentations on DNL310 (ETV:IDS) Development Program in MPS II (Hunter Syndrome) at the Upcoming WORLDSymposium™

01 2 2022 09:00:01 提供 Nasdaq GlobeNewswire